Iteos Therapeutics Inc to Discuss Collaboration with GlaxoSmithKline PLC for EOS-448 Call Transcript
Good morning, and welcome to the iTeos Therapeutics Business Update Conference Call. (Operator Instructions) Please be advised this call is being recorded at the company's request.
At this time, I'd like to turn it over to Ryan Baker, Head of Investor Relations at iTeos.
Thank you for joining us today. Joining me from iTeos are Michel Detheux, President and CEO; Matthew Gall, Chief Financial Officer; Matt Call, Chief Operating Officer; and Dr. Jo Lager, Chief Medical Officer. This morning, iTeos issued a news release announcing that it has entered into a partnership with GlaxoSmithKline to co-develop and co-commercialize iTeos' anti-TIGIT antibody, EOS-448, as a potential treatment for people with cancer.
Before I turn the call over to Michel to discuss the details of the partnership, I would like to note that the team will be making forward-looking statements in the prepared remarks and during the Q&A session. Please take a moment to review Slide #2 on the webcast, which contains our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |